Osteoporosis: Romosozumab from Amgen Succeeds in Preventing Bone Fracture

Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study of Romosozumab In Postmenopausal Women With Osteoporosis
The FRAME Study Met All Primary Endpoints by Reducing the Incidence of New Vertebral Fracture Through 12 and 24 Months

Amgen (AMGN)and UCB (Euronext Brussels: UCB): Top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME). The results  showed FRAME met the co-primary endpoints by reducing the incidence of new vertebral fracture through months 12 . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.